全文获取类型
收费全文 | 8698篇 |
免费 | 410篇 |
国内免费 | 49篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 259篇 |
妇产科学 | 126篇 |
基础医学 | 1030篇 |
口腔科学 | 152篇 |
临床医学 | 627篇 |
内科学 | 1979篇 |
皮肤病学 | 295篇 |
神经病学 | 679篇 |
特种医学 | 236篇 |
外科学 | 1458篇 |
综合类 | 30篇 |
预防医学 | 284篇 |
眼科学 | 192篇 |
药学 | 680篇 |
中国医学 | 19篇 |
肿瘤学 | 1060篇 |
出版年
2023年 | 43篇 |
2022年 | 27篇 |
2021年 | 141篇 |
2020年 | 118篇 |
2019年 | 148篇 |
2018年 | 173篇 |
2017年 | 137篇 |
2016年 | 180篇 |
2015年 | 201篇 |
2014年 | 224篇 |
2013年 | 324篇 |
2012年 | 474篇 |
2011年 | 638篇 |
2010年 | 333篇 |
2009年 | 284篇 |
2008年 | 529篇 |
2007年 | 616篇 |
2006年 | 620篇 |
2005年 | 603篇 |
2004年 | 597篇 |
2003年 | 602篇 |
2002年 | 631篇 |
2001年 | 87篇 |
2000年 | 103篇 |
1999年 | 108篇 |
1998年 | 150篇 |
1997年 | 99篇 |
1996年 | 112篇 |
1995年 | 85篇 |
1994年 | 86篇 |
1993年 | 64篇 |
1992年 | 68篇 |
1991年 | 71篇 |
1990年 | 62篇 |
1989年 | 63篇 |
1988年 | 46篇 |
1987年 | 51篇 |
1986年 | 30篇 |
1985年 | 33篇 |
1984年 | 27篇 |
1983年 | 17篇 |
1982年 | 14篇 |
1981年 | 17篇 |
1980年 | 20篇 |
1979年 | 14篇 |
1978年 | 16篇 |
1977年 | 16篇 |
1975年 | 7篇 |
1974年 | 8篇 |
1970年 | 8篇 |
排序方式: 共有9157条查询结果,搜索用时 15 毫秒
1.
Maruyama Jessica Mayumi Santos Iná S. Munhoz Tiago Neuenfeld Matijasevich Alicia 《European child & adolescent psychiatry》2021,30(12):1939-1948
European Child & Adolescent Psychiatry - There is growing evidence that adolescent positive attributes and social aptitudes are associated with beneficial outcomes, including higher educational... 相似文献
2.
3.
Takahiro Hosokawa Hiroaki Takahashi Yutaka Tanami Yumiko Sato Mayumi Hosokawa Eiji Oguma 《Journal of ultrasound in medicine》2019,38(2):533-538
Portal venous gas is occasionally encountered in children with intestinal pneumatosis, identified on real‐time ultrasound imaging as hyperechoic foci with quick movement. The origin of the portal venous gas can be identified by following the hyperechoic foci along the branches of the portal vein, providing an estimate of the location of intestinal pneumatosis. This approach may be useful for predicting the patient's prognosis. Our report describes 2 cases of portal venous gas while estimating the area of intestinal pneumatosis, which were evaluated with real‐time ultrasound. 相似文献
4.
5.
6.
Yoshida Akihito Motomura Kazuya Natsume Atsushi Chalise Lushun Iijima Kentaro Hara Daisuke Kadono Izumi Wakai Kenji Wakabayashi Toshihiko 《Journal of neuro-oncology》2020,146(1):195-205
Journal of Neuro-Oncology - This study aimed to investigate the preoperative predictive factors affecting return to work in patients with gliomas in the left cerebral hemisphere undergoing awake... 相似文献
7.
8.
9.
10.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献